Receive our newsletter – data, insights and analysis delivered to you
  1. News
June 9, 2021updated 10 Jun 2021 3:38am

Bayer studies cell and gene therapies for Parkinson’s disease

Bayer’s cell and gene therapy candidates are currently being analysed in Phase I clinical trials for Parkinson’s.

Bayer subsidiary BlueRock Therapeutics has dosed the first subject in an open-label Phase I clinical study of its pluripotent stem cell-derived dopaminergic neurons, DA01, to treat Parkinson’s disease.

A neurodegenerative movement disorder, Parkinson’s disease arises due to damage of nerve cells in the brain. It is known to affect more than ten million people globally.

BlueRock plans to leverage dopaminergic neurons to re-innervate the affected brain areas and reverse the degeneration process for possible restoration of motor function.

The Phase I trial will include ten subjects enrolled at sites in the US and Canada.

Participants will undergo a procedure to transplant dopamine-producing cells into the putamen, which is a deep brain structure impacted by Parkinson’s disease.

Evaluating the safety and tolerability of DA01 cell transplantation a year after transplant will be the trial’s primary goal.

Content from our partners
The importance of reference products in biosimilar trials, and how to source them
Africa’s last mile: Building viable vaccine supply chains
Why this global life sciences COO believes relocation to Charleston, SC, was key to achieving next-level success

The indication of transplanted cell survival and motor effects at one and two years after transplant will be included as secondary goals, along with continued safety and tolerability at two years and transplantation feasibility.

Parallelly, Bayer’s clinical-stage adeno-associated virus (AAV) gene therapy company, Asklepios BioPharmaceutical (AskBio), is developing a gene therapy programme that could potentially offer advanced treatments for Parkinson’s disease.

AskBio’s therapy leverages an AAV to carry the human glial cell line-derived neurotrophic factor (GDNF) gene to the neurons in the putamen. This process causes GDNF protein expression and secretion in areas of the brain affected by the disease.

According to data from long-term experiments with AAV-GDNF in rodents as well as non-human primate models, consistent expression of GDNF demonstrated the ability to induce regeneration of midbrain neurons and substantial motor recovery.

At present, this gene therapy programme is being evaluated for safety and initial efficacy in a Phase Ib clinical study in the US.

This trial, which was initiated in August last year, has enrolled a total of ten subjects so far.

Bayer Cell and Gene Therapy head Wolfram Carius said: “The potential of BlueRock and AskBio’s clinical candidates to treat Parkinson’s disease could be immense.

“For the first time, it might be possible to stop and reverse this degenerative disease and truly help patients with their high unmet medical need.”

In October last year, Bayer reported that the Phase III CHRONOS-3 trial of Aliqopa plus rituximab to treat patients with relapsed indolent Non-Hodgkin’s Lymphoma met its primary endpoint.

Related Companies

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU